<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147822</url>
  </required_header>
  <id_info>
    <org_study_id>113078</org_study_id>
    <nct_id>NCT01147822</nct_id>
  </id_info>
  <brief_title>Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma - A Substudy to VEG108844</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to provide a direct comparison of the efficacy, safety, and
      tolerabilityfor pazopanib and sunitinib (SUTENT) in the Asian population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate efficacy and safety of pazopanib versus sunitinib for the
      treatment of Asian subjects with locally advanced and/or metastatic renal cell carcinoma
      (RCC) enrolled from selected Far-East Asian countries. The primary objective is to evaluate
      the primary endpoint progression free survival in the enrolled Asian subjects treated with
      pazopanib versus those treated with sunitinib. The secondary objectives are to evaluate the
      following secondary endpoints in each treatment arm: objective response rate, duration of
      response, time to response, overall survival and safety. Subjects will be randomized in a 1:1
      ratio to receive either 800mg pazopanib to be administered once daily orally continuous
      dosing or 50mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks
      followed by 2 weeks off treatment. Subjects are permitted to receive supportive care
      throughout the study including transfusion of blood and blood products, treatment with
      antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoietin, or
      bisphosphonates, when appropriate. The study treatment will continue until subjects
      experience disease progression, unacceptable toxicity, withdraw consent, or death.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 19, 2010</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 21, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization to the earliest date of disease progression or death (up to 39 months)</time_frame>
    <description>PFS is defined as the interval between the date of randomization and the earliest date of progressive disease (PD), as defined by the Independent Review Committee (IRC), or death due to any cause. The IRC defined PD per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1. Per RECIST, PD is defined as a &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter (LD) recorded since the treatment started or the appearance of &gt;=1 new lesion. Participants who had neither progressed nor died were censored at the date of the last adequate tumor assessment at the time of the cut-off.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 44 months)</time_frame>
    <description>OS is defined as the time from randomization until death due to any cause. Participants who had not died were censored at the date of the last adequate tumor assessment at the time of the cut-off.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Best Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the IRC</measure>
    <time_frame>From Baseline until the time of response or the earliest date of disease progression/death (up to 39 months)</time_frame>
    <description>The number of participants with evidence of CR (the disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters [mm] in the short axis) or PR (at least a 30% decrease in the sum of the longest diameters [LD] of target lesions, taking as a reference the Baseline sum LD) was evaluated by an independent review per RECIST, Version 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>From Baseline until the time of response or the earliest date of disease progression/death (up to 39 months)</time_frame>
    <description>Time to response is defined as the time from the start of treatment until the first documented evidence of confirmed CR (the disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD), whichever comes first. CR and PR were evaluated by an independent review per RECIST, Version 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the time of response until the earliest date of disease progression/death (up to 38 months)</time_frame>
    <description>DOR is defined as the time from the first documented evidence of confirmed response (CR or PR) until the first documented sign of disease progression (a &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of &gt;=1 new lesion) or death, if sooner. CR=the disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis. PR=at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg administered once daily orally continuous dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg sunitinib to be administered in 6-week cycles: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>800 mg administered once daily orally continuous dosing</description>
    <arm_group_label>Pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment</description>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Diagnosis of renal cell carcinoma with clear-cell component histology.

          -  Received no prior systemic therapy (interleukin-2, interferon-alpha, chemotherapy,
             bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI) for advanced or
             metastatic RCC

          -  Locally advanced or metastatic renal cell carcinoma Measurable disease by CT or MRI

          -  Karnofsky performance scale status of &gt;=70

          -  Age &gt;=18 years

          -  A female is eligible to enter and participate in this study if she is of:
             non-childbearing or agrees to use adequate contraception.

          -  Adequate organ system function

          -  Total serum calcium concentration &lt;12.0mg/dL

          -  Left ventricular ejection fraction &gt;= lower limit of institutional normal

        Exclusion Criteria:

          -  Pregnant or lactating female (unless agrees to refrain from nursing throughout the
             treatment period and for 14 days following the last dose of study)-History of another
             malignancy (unless have been disease-free for 3 years)

          -  History or clinical evidence of central nervous system (CNS) metastases (unless have
             previously-treated CNS metastases and meet all 3 of the following criteria are: are
             asymptomatic, have had no evidence of active CNS metastases for &gt;=6 months prior to
             enrolment, and have no requirement for steroids or enzyme-inducing anticonvulsants)

          -  Clinically significant gastrointestinal abnormalities including, but not limited to:
             malabsorption syndrome, major resection of the stomach or small bowel that could
             affect the absorption of study drug, active peptic ulcer disease, known intraluminal
             metastatic lesion/s with suspected bleeding, Inflammatory bowel disease, ulcerative
             colitis, or other gastrointestinal conditions with increased risk of perforation,
             history of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess
             within 28 days prior to beginning study treatment

          -  Presence of uncontrolled infection

          -  Prolongation of corrected QT interval (QTc) &gt; 480 milliseconds

          -  History of any one or more of the following cardiovascular conditions within the past
             12 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina,
             coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, Class
             III or IV congestive heart failure, as defined by the New York Heart Association

          -  History of cerebrovascular accident including transient ischemic attack within the
             past 12 months

          -  History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the
             past 6 months (unless had recent DVT and have been treated with therapeutic
             anti-coagulating agents for at least 6 weeks)

          -  Poorly controlled hypertension (defined as systolic blood pressure of &gt;=150mmHg or
             diastolic blood pressure of &gt;=90mmHg). Initiation or adjustment of antihypertensive
             medication(s) is permitted prior to study entry

          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
             presence of any non-healing wound, fracture, or ulcer.

          -  Evidence of active bleeding or bleeding susceptibility

          -  Spitting/coughing up blood within 6 weeks of first dose of study drug

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other conditions
             that could interfere with patient's safety, obtaining informed consent or compliance
             to the study

          -  Use any prohibited medications within 14 days of the first dose of study medication

          -  Use of an investigational agent, including an investigational anti-cancer agent,
             within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study
             drug

          -  Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors
             (eg. bevacizumab, sunitinib, sorafenib, etc), or are mTOR inhibitors (eg.
             temsirolimus, everolimus, etc).

          -  Is now undergoing and/or has undergone in the 14 days immediately prior to first dose
             of study drug, any cancer therapy (surgery, tumor embolization, chemotherapy,
             radiation therapy, immunotherapy, biological therapy, or hormonal therapy)

          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that is
             progressing in severity

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to pazopanib or sunitinib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goyang-si, Gyeonggi-Do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung Hsien</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUTENT</keyword>
  <keyword>GW76034</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Pazopanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study VEG113078 is a substudy of Study VEG108844 (NCT00720941). Due to the projected limited enrollment of Asian participants into Study VEG108844, Study VEG113078 was designed to evaluate the efficacy and safety of pazopanib versus sunitinib for the treatment of Asian participants (par.) enrolled from selected Far-East Asian countries.</recruitment_details>
      <pre_assignment_details>Par. from China, Korea, and Taiwan who enrolled in either Study VEG108844 or VEG113078 and par. from Japan who enrolled in Study VEG108844 were pooled for analysis of the Asian population, presented in this report. Only 183 participants were enrolled in Study VEG113078 (as reflected in the Enrollment field in the Protocol record).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pazopanib 800 mg</title>
          <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
        </group>
        <group group_id="P2">
          <title>Sunitinib 50 mg</title>
          <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Completed/Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Completed/Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pazopanib 800 mg</title>
          <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
        </group>
        <group group_id="B2">
          <title>Sunitinib 50 mg</title>
          <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="179"/>
            <count group_id="B3" value="367"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="11.51"/>
                    <measurement group_id="B2" value="57.6" spread="11.19"/>
                    <measurement group_id="B3" value="57.6" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined as the interval between the date of randomization and the earliest date of progressive disease (PD), as defined by the Independent Review Committee (IRC), or death due to any cause. The IRC defined PD per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1. Per RECIST, PD is defined as a &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter (LD) recorded since the treatment started or the appearance of &gt;=1 new lesion. Participants who had neither progressed nor died were censored at the date of the last adequate tumor assessment at the time of the cut-off.</description>
        <time_frame>From randomization to the earliest date of disease progression or death (up to 39 months)</time_frame>
        <population>Intent-to-Treat (ITT) Population (Asian): All randomized participants (par) from Study VEG113078 and Study VEG108844 who enrolled in Japan, China, Taiwan, and Korea.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib 800 mg</title>
            <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib 50 mg</title>
            <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is defined as the interval between the date of randomization and the earliest date of progressive disease (PD), as defined by the Independent Review Committee (IRC), or death due to any cause. The IRC defined PD per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1. Per RECIST, PD is defined as a &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter (LD) recorded since the treatment started or the appearance of &gt;=1 new lesion. Participants who had neither progressed nor died were censored at the date of the last adequate tumor assessment at the time of the cut-off.</description>
          <population>Intent-to-Treat (ITT) Population (Asian): All randomized participants (par) from Study VEG113078 and Study VEG108844 who enrolled in Japan, China, Taiwan, and Korea.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="8.3" upper_limit="11.1"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8.2" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.0184</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7658</ci_lower_limit>
            <ci_upper_limit>1.3542</ci_upper_limit>
            <estimate_desc>The HR was estimated by the Cox regression model using treatment stratification factors as covariates. The HR was adjusted for Karnofsky Performance Scale scores, prior nephrectomy, and Baseline levels of lactate dehydrogenase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from randomization until death due to any cause. Participants who had not died were censored at the date of the last adequate tumor assessment at the time of the cut-off.</description>
        <time_frame>From randomization until death (up to 44 months)</time_frame>
        <population>ITT Population (Asian)</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib 800 mg</title>
            <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib 50 mg</title>
            <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as the time from randomization until death due to any cause. Participants who had not died were censored at the date of the last adequate tumor assessment at the time of the cut-off.</description>
          <population>ITT Population (Asian)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="23.7">An insufficient number of participants were followed until death; thus, the median could not be calculated. An insufficient number of participants were followed until death; thus, the upper limit of the confidence interval could not be calculated.</measurement>
                    <measurement group_id="O2" value="31.5" lower_limit="29.5">An insufficient number of participants were followed until death; thus, the upper limit of the confidence interval could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Best Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the IRC</title>
        <description>The number of participants with evidence of CR (the disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters [mm] in the short axis) or PR (at least a 30% decrease in the sum of the longest diameters [LD] of target lesions, taking as a reference the Baseline sum LD) was evaluated by an independent review per RECIST, Version 1.</description>
        <time_frame>From Baseline until the time of response or the earliest date of disease progression/death (up to 39 months)</time_frame>
        <population>ITT Population (Asian)</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib 800 mg</title>
            <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib 50 mg</title>
            <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Best Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the IRC</title>
          <description>The number of participants with evidence of CR (the disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters [mm] in the short axis) or PR (at least a 30% decrease in the sum of the longest diameters [LD] of target lesions, taking as a reference the Baseline sum LD) was evaluated by an independent review per RECIST, Version 1.</description>
          <population>ITT Population (Asian)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time to response is defined as the time from the start of treatment until the first documented evidence of confirmed CR (the disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD), whichever comes first. CR and PR were evaluated by an independent review per RECIST, Version 1.</description>
        <time_frame>From Baseline until the time of response or the earliest date of disease progression/death (up to 39 months)</time_frame>
        <population>ITT Population (Asian). Only those participants who experienced either a confirmed CR or a PR were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib 800 mg</title>
            <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib 50 mg</title>
            <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response is defined as the time from the start of treatment until the first documented evidence of confirmed CR (the disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD), whichever comes first. CR and PR were evaluated by an independent review per RECIST, Version 1.</description>
          <population>ITT Population (Asian). Only those participants who experienced either a confirmed CR or a PR were analyzed.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="6.7" upper_limit="12.3"/>
                    <measurement group_id="O2" value="17.9" lower_limit="12.0" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR is defined as the time from the first documented evidence of confirmed response (CR or PR) until the first documented sign of disease progression (a &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of &gt;=1 new lesion) or death, if sooner. CR=the disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis. PR=at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD.</description>
        <time_frame>From the time of response until the earliest date of disease progression/death (up to 38 months)</time_frame>
        <population>ITT Population (Asian). Only those participants who experienced either a confirmed CR or a PR were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib 800 mg</title>
            <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib 50 mg</title>
            <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>DOR is defined as the time from the first documented evidence of confirmed response (CR or PR) until the first documented sign of disease progression (a &gt;=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of &gt;=1 new lesion) or death, if sooner. CR=the disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis. PR=at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the Baseline sum LD.</description>
          <population>ITT Population (Asian). Only those participants who experienced either a confirmed CR or a PR were analyzed.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="9.9" upper_limit="17.9"/>
                    <measurement group_id="O2" value="18.0" lower_limit="12.3">An insufficient number of responders were followed until progression to observe the end of response; thus, the upper limit of the confidence interval could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were analyzed from the first dose of study medication until the follow-up contact (up to Study Week 156).</time_frame>
      <desc>Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprised of all randomized participants who received at least one dose of study medication, according to the actual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pazopanib 800 mg</title>
          <description>Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
        </group>
        <group group_id="E2">
          <title>Sunitinib 50 mg</title>
          <description>Participants were administered sunitinib 50 mg capsules orally OD in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Study treatment continued until participants experienced disease progression, death, or unacceptable toxicity, or withdrew consent for any other reason.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Small intestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperlipasemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tumour rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tumour hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Central nervous system hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Laryngeal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Xanthochromia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

